Доклиническая кардиотоксичность при системном лечении резектабельного рака молочной железы

Исследование онкологических пациентов с оценкой риска кардиотоксичности химиопрепаратов осуществлялось с использованием диагностических методов: эхокардиографии с оценкой глобальной деформации миокарда, магнитно-резонансной томографии сердца, анализа сердечных биомаркеров и жесткости артерий. Применение указанных методов позволило выявить субклиническое поражение сердца и сосудов у пациентов при системном лечении пациентов с резектабельным раком молочной железы.

1. Chazova I.E., Ageev F.T., Aksenova A.V., Vitsenja M.V., Giljarov M.Ju., Martynjuk T.V., Panchenko E.P., Poltavskaja M.G., Potievskaja V.I., Trofimova O.P., Fedotkina Ju.A. Evrazijskie klinicheskie rekomendatsii po diagnostike, profilaktike i lecheniju serdechno-sosudistyh oslozhnenij pri protivoopuholevoj terapii [Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment]. Eurasian heart journal, 2022, vol. 37, no. 1. doi: 10.38109/2225-1685-2022-1-6-79 (in Russion).

2. Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D.J., de Azambuja E., de Boer R.A., Dent S.F., Farmakis D., Gevaert S.A., Gorog D.A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S.S., Stephens R., Suter T.M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C.G., van der Meer P., van der Pal H.J.H.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J, 2022, vol. 43(41), pp. 4229-4361. doi: 10.1093/eurheartj/ehac244.

3. Curigliano G., Lenihan D., Fradley M., et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol, 2020, vol. 31, no. 2, pp. 171-190. doi: 10.1016/j.annonc.2019.10.023.

4. Papageorgiou C., Andrikopoulou A., Dimopoulos M.A., Zagouri F. Cardiovascular toxicity of breast cancer treatment: an update. Cancer Chemother Pharmacol, 2021, vol. 88(1), pp. 15-24. doi: 10.1007/s00280-021-04254-w.

5. Ram P., Tiu A., Lo K. B., Parikh K., Shah M. Trends in the prevalence of malignancy among patients admitted with acute heart failure and associated outcomes: a nationwide population-based study. Heart Failure Reviews, 2019, vol. 24, no. 6, pp. 989-995. doi: 10.1007/s10741-019-09808-y.

6. Larsen C.M., Mulvagh S.L. Cardio-oncology: what you need to know now for clinical practice and echocardiography. Echo Res Prat, 2017. vol. 4, no. 1, pp. 33-41. doi:10.1530/ERP-17-0013.

7. Fei H.W., Ali M.T., Tan T.C., et al. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction. Echocardiography, 2016, vol. 33, no. 4. pp. 519-26. doi:10.1111/echo.13168.

8. Calle M.C., Sandhu N.P., Xia H., et al. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer. BMC Cancer, 2018, vol. 18. doi:10.1186/ s12885-018-4935-z.

9. Tu C., Shen H., Liu R., Wang X., Li X., Yuan X., Chen Q., Wang Y., Ran Z., Lan X., Zhang X., Lin M., Zhang J. Myocardial extracellular volume derived from contrast-enhanced chest computed tomography for longitudinal evaluation of cardiotoxicity in patients with breast cancer treated with anthracyclines. Insights Imaging, 2022, vol. 13(1), pp. 85. doi: 10.1186/s13244-022-01224-5.

10. Souza C.A., Simões R., Borges K.B.G., Oliveira A.N., Zogeib J.B., Alves B., Malachias MVB, Drummond-Lage A.P., Rezende B.A. Arterial Stiffness Use for Early Monitoring of Cardiovascular Adverse Events due to Anthracycline Chemotherapy in Breast Cancer Patients. A Pilot Study. Arq Bras Cardiol, 2018, vol. 111, no. 5, pp.721-728. doi: 10.5935/abc.20180168.

11. Parr SK, Liang J, Schadler KL, Gilchrist SC, Steele CC, Ade CJ. Anticancer Therapy-Related Increases in Arterial Stiffness: A Systematic Review and Meta-Analysis. J Am Heart Assoc, 2020, vol. 9(14), e015598. doi: 10.1161/JAHA.119.015598.